A four-year follow-up survey of antimicrobial resistance among Acinetobacter baumannii complex from inpatients in Southern Brazil.

OBJECTIVES: To determine the trends of antimicrobial resistance for Acinetobacter baumannii complex isolates recovered from inpatients over a 4-year follow-up survey. METHODS: A total of 659 A baumannii complex isolates were recovered from hospitalized patients in Porto Alegre and its metropolitan area, Southern Brazil, from 2017 to 2020. Susceptibility profile was determined for ampicillin/sulbactam, amikacin, gentamicin, imipenem, meropenem, minocycline, polymyxin B and tigecycline. RESULTS: Overall, PMB was the most active agent against the set of A baumannii isolates over the period. Although stable, a high resistance rate was observed. CONCLUSIONS: Our results shown the presence of an extensively-drug resistant A baumannii complex isolates over the past four years. Polymyxin B has been the only antimicrobial agent that remain with a good in vitro activity. Strict surveillance and infection control measures are mandatory.

Impact of the blue-carba rapid test for carbapenemase detection on turnaround time for an early therapy against Pseudomonas aeruginosa.

BACKGROUND: To determine the turnaround time from a blue-carba result until a final microbiological report (bacterial identification plus antimicrobial susceptibility profile) and to infer the impact of an early therapeutic intervention based on the blue-carba results. METHODS: Pseudomonas aeruginosa isolates were recovered from hospitalized patients from Porto Alegre, Brazil, and tested by blue-carba test. Time required for a blue-carba result, right after the sample processing, was compared with those required to get final report (specie identification and antimicrobial susceptibility profile) Isolates blue-carba positive were tested by phenotypically and genotypically for Klebsiella pneumoniae carbapenemase and metallo-ß-lactamase genes. RESULTS: A total of 199 isolates were analyzed and 23 (11.6%) were blue-carba positive and harboring the blaSPM-1-like gene. Fifty-two (26.1%) isolates were blue-carba negative but resistant to meropenem and/or imipenem. Polymyxin B and ceftolozane/tazobactam (this latter except for SPM-1 producers) were 100% active for all P. aeruginosa isolates, a blue-carba test allow an earlier intervention or adequacy of therapy. CONCLUSIONS: Early adequacy can be promoted by blue-carba test for 11.6% of SPM-1-producing P. aeruginosa isolates, polymyxin B could be prior associated and ceftolozane/tazobactam withdrawn from therapy. For the remaining isolates, empirical therapy involving ceftolozane/tazobactam can be maintained with greater likelihood of adequacy. An active communication between laboratory and clinical services is necessary to better explore these earlier blue-carba results, significantly reducing the time for a first intervention.

Evaluation of a polymyxin drop test for polymyxin resistance detection among non-fermentative gram-negative rods and enterobacterales resistant to carbapenems.

To assess the performance of the drop test for polymyxin B resistance detection among Enterobacterales and non-fermentative gram-negative rods resistant to carbapenems. Seven hundred and fifteen carbapenem-resistant isolates were tested: 628 Enterobacterales species and 87 non-fermentative gram-negative rods. For the polymyxin drop test, concentrations range from 0.25 to 8.0 µg/mL. Broth microdilution, as gold standard, was performed using in-house-prepared panels and interpreted according to the CLSI guidelines. Results were interpreted in terms of categorical agreements and discrepancies. Accuracy for a drop of polymyxin B at 2.0, 4.0 and 8.0 was calculated as better cutoff for resistance determination. No very major error was observed among all isolates, and 95.5% of agreement was observed among Enterobacterales, particularly for Klebsiella pneumoniae. A higher accuracy (95.1%) was obtained when a single drop of polymyxin B at 4.0 µg/mL was applied. Polymyxin drop test presented >95% of categorical agreement, without very major errors, for KPC-producing K. pneumoniae isolates. An accuracy of 95.1% was obtained with a single drop at 4.0 µg/mL polymyxin B. Polymyxin B drop is an easy and feasible test and may allow a reduction on the turnaround time for polymyxin resistance detection and impacting on early implementation of accurate therapeutic interventions.

Emergence of vanA vancomycin-resistant Enterococcus faecium in a hospital in Porto Alegre, South Brazil.

INTRODUCTION: In Porto Alegre (South Brazil), since the first VRE isolation in 2000 until the middle of the last decade, the epidemiology of enterococcal infections presented the peculiarity that, as opposed to other regions of the country, almost all VRE were E. faecalis. The aim of this study was to investigate the microbiological and epidemiological characteristics of a VRE outbreak that occurred between August 2010 and September 2011 in Porto Alegre, South Brazil. METHODOLOGY: Twenty-nine isolates from inpatients of Mãe de Deus Hospital that were identified and characterized for their susceptibility profile, vancomycin genotype, presence of esp gene, biofilm production, and clonal relationship were collected.  Patients' records were reviewed for clinical information. RESULTS: All isolates were identified as vancomycin/ampicillin resistant E. faecium carrying the vanA gene. Almost all were susceptible to gentamicin and streptomycin. Most patients died and were associated with a hemodialysis unit stay. All but the first isolate were clustered in a main clone. CONCLUSIONS: An important change in vancomycin-resistant enterococci was observed. Studies like this are necessary to monitor the dissemination of VRE, especially of some individual clones.

Síndromes de mononucleose / Mononucleosis syndromes

Este artigo aborda o diagnóstico diferencial entre algumas das principais causas de síndrome mononucleose-like, bem como o seu manejo inicial pelo clínico.

This article discusses the differential diagnosis between some of the main causes of mononucleosis-like illnesses, as well as their initial management by the clinician.

CA-MRSA em furunculose: relato de caso do sul do Brasil / CA MRSA in furunculosis: case report of Southern Brazil

Staphylococcus aureus resistente à meticilina (MRSA), outrora isolado especificamente em ambientes hospitalares, vem sendo identificado como causador de infecções cutâneas em pacientes da comunidade. Neste artigo, é relatado um caso do sul do Brasil com furunculose por CA-MRSA. O microrganismo isolado foi submetido a exames de PCR para o gene mecA e para o gene que codifica a leucocidina de Panton-Valentine. Esses exames permitiram a identificação genotípica do CA-MRSA.

Methicillin-resistant Staphylococcus aureus (MRSA), particularly isolated at hospital setting, has been identified in cutaneous infections of community patients. This paper reports a case of furunculosis from the southern Brazil. Dermatologists must be attentive to this emergent etiological diagnosis. The isolated microorganism was subjected to PCR for gene mecA and to PCR for the gene that encodes the leukocidin of Panton-Valentine. These exams enabled genotypic identification of CA-MRSA.

[CA MRSA in furunculosis: case report of southern Brazil]. / CA-MRSA em furunculose: relato de caso do sul do Brasil.

Methicillin-resistant Staphylococcus aureus (MRSA), particularly isolated at hospital setting, has been identified in cutaneous infections of community patients. This paper reports a case of furunculosis from the southern Brazil. Dermatologists must be attentive to this emergent etiological diagnosis. The isolated microorganism was subjected to PCR for gene mecA and to PCR for the gene that encodes the leukocidin of Panton-Valentine. These exams enabled genotypic identification of CA-MRSA.

Principais efeitos adversos da terapia antiretroviral / Main adverse effects of antiretroviral therapy

Os autores fazem uma rápida revisão bibliográfica sobre os principais efeitos adversos da terapia anti-retroviral para a AIDS/HlV, dando ênfase aos seus sinais diagnósticos a fim de evitar complicações potencialmente letais, como a acidose láctica e outros problemas menos graves, porém mais comuns, que estão ficando mais freqüentes com a intensificação do uso dos fármacos anti-retrovirais e a maior expectativa de vida dos pacientes com HIV

Histoplasmose / Histoplasmosis

Os autores desenvolvem uma revisão abrangente da literatura disponível sobre o tema, permitindo a obtenção de informações atualizadas e úteis para a prática clínica. Abordam-se aspectos epidemiológicos, clínicos, diagnósticos e terapêuticos da doeça causada pelo Histoplasma capsulatum, alertando para o risco de doença disseminada em pacientes imunodeprimidos, especialmente com HIV, como infeção oportunista